Skip to main content
Tag

regenerative medicine Archives - BioHealth Innovation

Maryland’s Quantum Moment: Turning Research Leadership into Life Science Commercialization

By News

From September 23–25, more than 2,000 leaders from industry, government, academia, investment, and research gathered in College Park, Maryland, for the 2026 Quantum World Congress. Held at The Hotel at the University of Maryland, the three-day event brought the global quantum community directly into one of the country’s most concentrated quantum ecosystems.


The University of Maryland served as the Congress’s Lead Academic Partner, while platinum sponsors included Atom Computing, Classiq, D-Wave, IBM, Infleqtion, IonQ, Microsoft, and Quantinuum. For Maryland, the location was meaningful. College Park and the surrounding BioHealth Capital Region are home to major quantum research programs, federal assets, emerging companies, and industry leaders including IonQ, creating a foundation few regions can match.

For BioHealth Innovation, Inc. (BHI), the Congress also reinforced an opportunity that extends beyond quantum computing itself: bringing Maryland’s strengths in quantum together with one of the region’s other major competitive advantages, life sciences.

BHI President and CEO Rich Bendis participated in a Maryland-Canada roundtable that included Maryland Secretary of Commerce Harry Coker, Canadian Deputy Ambassador to the United States Nadia Theodore, IonQ leaders, researchers, commercialization leaders, and other participants from the U.S. and Canada. The Congress also featured IonQ Chairman and CEO Niccolo de Masi, underscoring IonQ’s central role in College Park’s quantum ecosystem. Bendis also serves on Maryland’s Life Sciences Advisory Board and is involved in the LSAB Ad-Hoc Quantum Commercialization Committee, which is examining how Maryland can translate its quantum assets into commercial life science opportunities.

“We have a goal to make Maryland the BioHealth Quantum Commercialization Capital of the World,” said Bendis.

That goal is closely aligned with BHI’s broader work to help define how the BioHealth Capital Region can move from research strength to companies, products, capital, jobs, and impact. BHI has been working with partners to frame the region’s quantum-biohealth opportunity around areas such as quantum sensing, diagnostics and early detection, imaging, drug discovery, computational biology, AI-enabled life sciences, federal health missions, and commercialization pathways.

The discussions at Quantum World Congress highlighted both the scale of Maryland’s opportunity and the growing competition surrounding it. States including Tennessee, Ohio, and Florida are developing quantum strategies and pursuing partnerships with major industry participants. Countries and international regions are doing the same. Companies such as IonQ are increasingly working across multiple states and markets as governments compete for investment, talent, research partnerships, and future commercial activity.

Maryland and the BioHealth Capital Region already possess many of the pieces needed to compete. UMD has decades of quantum research experience and more than 350 researchers working across quantum-related disciplines. College Park is home to IonQ and Quantum Catalyzer, or Q-Cat, which was created to help translate promising quantum technologies into new companies. The region also benefits from proximity to NIH, FDA, NIST, federal laboratories, defense and national security assets, major research universities, investors, and one of the nation’s strongest life science clusters.

Capital of Quantum adds another important layer. The five-year, $1 billion public-private initiative is helping organize the region’s quantum ecosystem around research, commercialization, workforce development, federal collaboration, infrastructure, and industry growth. For the BioHealth Capital Region, the question is how to connect that quantum momentum to biohealth use cases where the region can lead.

That is where commercialization becomes essential. Research strength alone will not determine which regions win. The winners will be the places that can connect science, intellectual property, experienced entrepreneurs, early-stage capital, industry demand, federal funding, and market strategy.

Quantum Catalyzer provides one early example of what this can look like. Based in College Park’s Discovery District, Q-Cat demonstrates how quantum sensing technologies can be productized, how IP can be created, how companies can be formed, and how industry and government demand can be connected to emerging quantum capabilities.

Discussions during the Congress pointed to opportunities in quantum sensing, regenerative medicine, computational biology, drug development, imaging, diagnostics, and other life science applications. They also underscored the need for commercialization expertise, early-stage capital, industry partnerships, and experienced talent capable of translating quantum research into products and companies.

International collaboration could play an important role as well. The Maryland-Canada roundtable identified potential areas where complementary life science and quantum capabilities could be brought together. Existing relationships between IonQ and Canadian organizations such as CCRM provide one model for exploring how quantum technologies could support new approaches in regenerative medicine and other areas.

The message coming out of Quantum World Congress was encouraging, but it also carried urgency.

Maryland and the BioHealth Capital Region have the research, companies, talent, federal connections, and life science infrastructure to establish a differentiated global position at the intersection of quantum and biohealth. Other regions are moving quickly, however, and leadership will depend on turning those assets into a coordinated commercialization strategy.

The opportunity is no longer theoretical. The next step is building the strategy, partnerships, funding mechanisms, and commercialization infrastructure needed to make this region the place where quantum-enabled life science discoveries move from research to market.

From Bavaria to BioHealth: BioM’s Ralf Huss on Building a Global Biotech Cluster

By BioTalk with Rich Bendis Podcast, News

In this episode of BioTalk with Rich Bendis, Ralf Huss, MD, PhD, Managing Director and CEO of BioM Biotech Cluster Development GmbH and spokesperson for the Bavarian Biotechnology Cluster, joins the conversation to discuss Bavaria’s biotechnology ecosystem and BioM’s role in moving science toward commercialization.

Ralf introduces BioM, the organization supporting biotech development in Munich and Bavaria for nearly 30 years, and shares how the cluster helps founders move from research ideas to company formation. The conversation touches on mentoring, boot camps, investor connections, entrepreneur-in-residence support, startup training, and physical incubation.

Listen now via your favorite podcast platform:
Apple: https://apple.co/4r9uzV7
Spotify: https://bit.ly/4cJvxS3
iHeart: https://ihr.fm/4gQHFDh
Amazon: https://amzn.to/4r9TtDW
YouTube: https://bit.ly/4r9b1Ah
TuneIn: https://bit.ly/3USac2L

Rich and Ralf also discuss the MAxL incubator, the m4 Award, and BioM’s work with more than 250 startups. Ralf shares his perspective on what early-stage teams need most, why strong science alone is not enough, and how business leadership, IP, financing, market need, and the right commercialization path all play a role.

The episode also explores emerging opportunities in biotech and medicine, including AI, digital medicine, quantum computing, nanotechnology, regenerative medicine, tech bio, and the growing convergence of biology, engineering, and advanced technologies. Ralf also discusses why international collaboration matters for regional biotech clusters and how Bavarian companies are thinking about U.S. partnerships, investors, market access, and connections to ecosystems like the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Ralf Huss, MD, PhD, is a physician-scientist, surgical pathologist, biotechnology executive, entrepreneur, and innovation leader with more than three decades of experience across academia, pharmaceutical research, biotechnology, digital pathology, regenerative medicine, and artificial intelligence in healthcare. He currently serves as Managing Director and CEO of BioM, the organization responsible for the development of the Bavarian Biotechnology Cluster, one of Europe’s leading life science ecosystems. Throughout his career, he has held leadership positions in multinational pharmaceutical companies, venture-backed biotechnology firms, international academic research and medical centers, and innovation organizations, with a particular focus on translational medicine, cell and gene therapy, digital medicine, and AI-driven diagnostics. He has been awarded numerous honors and published more than 180 peer-reviewed articles, books, and book chapters.

Technical.ly: Maryland’s stem cell research fund is filling the gap

By News

by: Karuga Koinange – Brian Jamieson founded Diagnostics Biochips to unlock the inner workings of the brain.

Based in Glen Burnie, the medical equipment manufacturing company develops tiny sensors that can be implanted to study electrical brain activity. The goal? To help find cures for neurological diseases like Parkinson’s, epilepsy and others.

Diagnostic Biochips also offers a data analysis platform called DBCloud that tracks and organizes the vast neural activity captured by its sensors. Together, these tools give researchers a window into what Jamieson describes as the brain’s “matrix.”

“If you’re probing a network or a computer and you want to see the 1s and 0s that make up the basic operation of a microprocessor, it’s the same thing with your brain,” Jamieson said. “What is the basic underlying machine-level code of your brain? It’s not a perfect metaphor, but it has some of the same characteristics in that you have all these basic elements that are connected.”

A loan that led to a new line of business

The State of Maryland’s venture capital arm, TEDCO, was one of the first to bet on Diagnostic Biochips, providing a seed investment that helped bring the company to life in 2013.

When the company first launched, it focused on building tools for in vivo applications, i.e., research with live animals. After a decade in this line of business, Jamieson had aspirations to scale up.

In 2023, he turned his attention to advanced stem cell models such as pluripotent stem cells (known as iPSCs) and 3D cultures called organoids. Brain organoid models are miniature, lab-grown versions of the human brain small enough to fit in a petri dish that replicate key properties of a developing, normal or diseased brain. Using these models, researchers can drastically boost the volume and efficiency of their data collection.

“Instead of doing individual surgeries on animals, now we’re scanning 96 brains at a time,” Jamieson said.

To support this pivot, Diagnostic Biochips started seeking funding for stem cell research. That search led Jamieson to apply for the Maryland Stem Cell Research Fund (MSCRF) in December 2024.

Click here to continue reading.

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.